(TNDM) Tandem Diabetes Care - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.435m USD | Total Return: 5.4% in 12m

Stock Insulin Pumps, Software, Cartridges, Infusion Sets
Total Rating 29
Safety 30
Buy Signal -0.70
Medical Devices -6.2
Health Care Equipment -3.7
Market Cap: 1,435m
Avg Trading Vol: 41.7M USD
ATR: 7.90%
Peers RS (IBD): 61.3
Risk 5d forecast
Volatility71.8%
Rel. Tail Risk-16.8%
Reward TTM
Sharpe Ratio0.31
Alpha-23.66
Character TTM
Beta1.333
Beta Downside-0.425
Drawdowns 3y
Max DD81.07%
CAGR/Max DD-0.28
EPS (Earnings per Share) EPS (Earnings per Share) of TNDM over the last years for every Quarter: "2021-03": -0.08, "2021-06": 0.06, "2021-09": 0.09, "2021-12": 0.16, "2022-03": -0.23, "2022-06": -0.24, "2022-09": -0.27, "2022-12": -0.25, "2023-03": -1.92, "2023-06": -0.55, "2023-09": -0.38, "2023-12": -0.27, "2024-03": -0.63, "2024-06": -0.48, "2024-09": -0.35, "2024-12": -0.4356, "2025-03": -0.6652, "2025-06": -0.78, "2025-09": -0.31, "2025-12": -0.01, "2026-03": 0,
EPS CAGR: 3.55%
EPS Trend: 24.3%
Last SUE: 2.41
Qual. Beats: 1
Revenue Revenue of TNDM over the last years for every Quarter: 2021-03: 141.037, 2021-06: 172.139, 2021-09: 179.627, 2021-12: 209.996, 2022-03: 175.907, 2022-06: 200.262, 2022-09: 204.547, 2022-12: 220.501, 2023-03: 169.383, 2023-06: 195.917, 2023-09: 185.622, 2023-12: 196.796, 2024-03: 191.674, 2024-06: 221.91, 2024-09: 363.289, 2024-12: 282.648, 2025-03: 234.422, 2025-06: 240.678, 2025-09: 249.253, 2025-12: 290.383, 2026-03: null,
Rev. CAGR: 14.30%
Rev. Trend: 68.9%
Last SUE: 0.28
Qual. Beats: 0
Risks
Technicals: volatile
Description: TNDM Tandem Diabetes Care

Tandem Diabetes Care, Inc. (TNDM) develops and commercializes technology for diabetes management. The companys primary offerings include insulin delivery systems, such as the t:slim X2 and Tandem Mobi insulin pumps. These devices operate within the medical device sector, which focuses on developing instruments and technologies for healthcare.

Tandems business model includes recurring revenue from single-use consumables like insulin cartridges and infusion sets, essential for pump operation. They also provide software solutions for device updates and data management, such as Tandem Device Updater and Tandem Source, which enhance user experience and data analysis for diabetes care. The company engages in research and development collaborations, exemplified by its partnership with the University of Virginia Center for Diabetes Technology, to advance automated insulin delivery systems. This highlights a common strategy in the medical technology industry: continuous innovation and strategic partnerships to improve patient outcomes.

For more detailed financial and operational data, consider exploring ValueRay.

Headlines to Watch Out For
  • New insulin pump adoption drives revenue growth
  • Recurring sales of consumables ensure stable income
  • Regulatory approvals critical for new product launches
  • Competition from alternative diabetes treatments impacts market share
  • Healthcare policy changes influence reimbursement rates
Piotroski VR‑10 (Strict) 2.5
Net Income: -204.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA -3.88 > 1.0
NWC/Revenue: 37.00% < 20% (prev 45.06%; Δ -8.07% < -1%)
CFO/TA -0.01 > 3% & CFO -9.72m > Net Income -204.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.55 > 1.5 & < 3
Outstanding Shares: last quarter (68.0m) vs 12m ago 2.81% < -2%
Gross Margin: 53.81% > 18% (prev 0.46%; Δ 5.33k% > 0.5%)
Asset Turnover: 109.8% > 50% (prev 109.5%; Δ 0.28% > 0%)
Interest Coverage Ratio: -23.93 > 6 (EBITDA TTM -174.6m / Interest Expense TTM 8.03m)
Altman Z'' -5.04
A: 0.43 (Total Current Assets 618.1m - Total Current Liabilities 242.7m) / Total Assets 881.1m
B: -1.42 (Retained Earnings -1.25b / Total Assets 881.1m)
C: -0.21 (EBIT TTM -192.2m / Avg Total Assets 924.4m)
D: -1.72 (Book Value of Equity -1.25b / Total Liabilities 725.9m)
Altman-Z'' Score: -5.04 = D
Beneish M -2.91
DSRI: 1.51 (Receivables 165.5m/114.6m, Revenue 1.01b/1.06b)
GMI: 0.86 (GM 53.81% / 46.21%)
AQI: 1.15 (AQ_t 0.09 / AQ_t-1 0.08)
SGI: 0.96 (Revenue 1.01b / 1.06b)
TATA: -0.22 (NI -204.7m - CFO -9.72m) / TA 881.1m)
Beneish M-Score: -2.91 (Cap -4..+1) = A
What is the price of TNDM shares? As of April 04, 2026, the stock is trading at USD 19.17 with a total of 1,688,589 shares traded.
Over the past week, the price has changed by -11.38%, over one month by -21.61%, over three months by -19.61% and over the past year by +5.38%.
Is TNDM a buy, sell or hold? Tandem Diabetes Care has received a consensus analysts rating of 3.71. Therefor, it is recommend to hold TNDM.
  • StrongBuy: 6
  • Buy: 4
  • Hold: 10
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the TNDM price?
Wallstreet Target Price 30.8 60.5%
Analysts Target Price 30.8 60.5%
TNDM Fundamental Data Overview as of 04 April 2026
P/E Forward = 1111.1111
P/S = 1.414
P/B = 10.929
Revenue TTM = 1.01b USD
EBIT TTM = -192.2m USD
EBITDA TTM = -174.6m USD
Long Term Debt = 310.0m USD (from longTermDebt, last quarter)
Short Term Debt = 24.4m USD (from shortTermDebt, last quarter)
Debt = 564.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 473.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.71b USD (1.43b + Debt 564.3m - CCE 292.7m)
Interest Coverage Ratio = -23.93 (Ebit TTM -192.2m / Interest Expense TTM 8.03m)
EV/FCF = -57.52x (Enterprise Value 1.71b / FCF TTM -29.7m)
FCF Yield = -1.74% (FCF TTM -29.7m / Enterprise Value 1.71b)
FCF Margin = -2.92% (FCF TTM -29.7m / Revenue TTM 1.01b)
Net Margin = -20.17% (Net Income TTM -204.7m / Revenue TTM 1.01b)
Gross Margin = 53.81% ((Revenue TTM 1.01b - Cost of Revenue TTM 468.7m) / Revenue TTM)
Gross Margin QoQ = 57.67% (prev 53.88%)
Tobins Q-Ratio = 1.94 (Enterprise Value 1.71b / Total Assets 881.1m)
Interest Expense / Debt = 0.37% (Interest Expense 2.08m / Debt 564.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -151.9m (EBIT -192.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.55 (Total Current Assets 618.1m / Total Current Liabilities 242.7m)
Debt / Equity = 3.64 (Debt 564.3m / totalStockholderEquity, last quarter 155.2m)
 Debt / EBITDA = -2.71 (negative EBITDA) (Net Debt 473.7m / EBITDA -174.6m)
 Debt / FCF = -15.97 (negative FCF - burning cash) (Net Debt 473.7m / FCF TTM -29.7m)
 Total Stockholder Equity = 144.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.15% (Net Income -204.7m / Total Assets 881.1m)
RoE = -142.0% (Net Income TTM -204.7m / Total Stockholder Equity 144.2m)
RoCE = -42.32% (EBIT -192.2m / Capital Employed (Equity 144.2m + L.T.Debt 310.0m))
 RoIC = -32.75% (negative operating profit) (NOPAT -151.9m / Invested Capital 463.7m)
 WACC = 7.74% (E(1.43b)/V(2.00b) * Re(10.67%) + D(564.3m)/V(2.00b) * Rd(0.37%) * (1-Tc(0.21)))
Discount Rate = 10.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 1.53%
 [DCF] Fair Price = unknown (Cash Flow -29.7m)
 EPS Correlation: 24.34 | EPS CAGR: 3.55% | SUE: 2.41 | # QB: 1
Revenue Correlation: 68.89 | Revenue CAGR: 14.30% | SUE: 0.28 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.29 | Chg7d=+0.003 | Chg30d=-0.002 | Revisions Net=+3 | Analysts=17
EPS current Year (2026-12-31): EPS=-0.79 | Chg7d=-0.001 | Chg30d=+0.008 | Revisions Net=+10 | Growth EPS=+69.4% | Growth Revenue=+6.0%
EPS next Year (2027-12-31): EPS=-0.02 | Chg7d=+0.005 | Chg30d=+0.019 | Revisions Net=+8 | Growth EPS=+97.6% | Growth Revenue=+11.7%
[Analyst] Revisions Ratio: +0.23 (8 Up / 5 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle